Immune biomarkers in triple-negative breast cancer: improving the predictivity of current testing methods
Triple-negative breast cancer (TNBC) poses a significant challenge in terms of prognosis
and disease recurrence. The limited treatment options and the development of resistance to …
and disease recurrence. The limited treatment options and the development of resistance to …
[HTML][HTML] Comparison of programmed cell death ligand 1 status between core needle biopsy and surgical specimens of triple-negative breast cancer
Purpose Pembrolizumab is currently used to treat advanced triple-negative breast cancer
(TNBC) and high-risk early TNBC with neoadjuvant chemotherapy (NAC). The tumor …
(TNBC) and high-risk early TNBC with neoadjuvant chemotherapy (NAC). The tumor …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - Springer
Abstract Background Immunohistochemical (IHC) PD-L1 expression is commonly employed
as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
[HTML][HTML] Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors
N Ilieva, M Pencheva, H Hadzhiev, D Tashkova… - Diagnostics, 2024 - mdpi.com
Background: This study aims to deliver more insights on the impact of neoadjuvant treatment
on Pd-L1 expression and to evaluate its correlation with clinicopathological factors …
on Pd-L1 expression and to evaluate its correlation with clinicopathological factors …
Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens
A Noske, K Steiger, S Ballke, M Kiechle… - Journal of Clinical …, 2024 - jcp.bmj.com
Aims Programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer (TNBC) is
important for immune checkpoint inhibitor therapies but may vary between different …
important for immune checkpoint inhibitor therapies but may vary between different …
Review of immune checkpoint blockade and PD-L1 testing in breast cancer
A Baltan, S Costache, AM Shaaban, C D'Arrigo - Diagnostic Histopathology, 2024 - Elsevier
In the past two decades, several drugs have been developed to modulate the immune
checkpoints. These modulators regulate, amongst others, the T-cell mediated immune …
checkpoints. These modulators regulate, amongst others, the T-cell mediated immune …
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
M Zdrenka, A Kowalewski, J Borowczak… - Clinical and …, 2023 - Springer
PD-L1 expression is known to predict the benefits of immune checkpoint inhibitor therapy for
triple-negative breast cancer (TNBC). We examined whether the PD-L1 expression …
triple-negative breast cancer (TNBC). We examined whether the PD-L1 expression …